An interventional study of Polygenic Risk Score and Digital app and wearable device in Coronary Heart Disease, sponsored by Catholic University of the Sacred Heart. Recruiting at 7 sites in Italy. Open to participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Catholic University of the Sacred Heart · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Coronary Disease with a site in Italy — 10 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Italy.
Among the 58 studies in Coronary Disease with a site in Italy, this one is the 28th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 17 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 56th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →10 of the 58 studies in Coronary Disease with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 18+
Robocath · Sites in Italy, Belgium, France and 3 more countries
Ages 18–120
Tampere University · Sites in Italy, Finland, Germany and 3 more countries
Ages 30–80
Fondazione GISE Onlus · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 40 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 476 across the 37 interventional studies, 1,000 across the 21 observational. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 58 have an industry lead sponsor. The 10 most frequent:
Catholic University of the Sacred Heart is the lead sponsor of 237 studies on the registry; 29 are open to participants now.
Catholic University of the Sacred Heart has 4 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04433052Tampere UniversityClinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD | 2026-12 |
| NCT01218776University of BolognaInternational Survey of Acute Coronary Syndromes | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 58 studies in Coronary Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the FITPREV (Feasibility of InnovaTive approaches for personalized cardiovascular PREVention: randomized controlled pilot trial and multidisciplinary evaluation for National Health Service implementation) clinical trial is to study the feasibility of innovative approaches( Polygenic Risk Score and health smartwatch) for personalized primary preventive interventions in cardiovascular diseases (CVD). The main questions it aims to answer are:
Participants will be randomized in one of the four parallel arms:
The primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.
Secondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.
This study aims to evaluate the feasibility and secondarily efficacy of disclosing cardiovascular genetic risk-in the setting of a general practitioner's office-in the promotion of healthier lifestyle behaviors.
The enrollment period will last 6 months, with each participant taking part in the study for 12. There are three key time points in the study, T0 or baseline (enrollment phase), T1 or disclosure visit after one month, T2 intermediate visit(after six months) and T3 or final visit at 12 months. At enrollment, participants will be classified into risk categories based on cardiovascular risk using the SCORE-2 or SCORE 2-OP tool. Individuals aged 40-69, without diabetes or congenital hypercolesterolemia, with a SCORE-2 between 2.5% and 10% and a diagnosys of metabolic syndrome according to the American Hearth Association Criteria will be enrolled.
Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes:
At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group.
The questionnaire will be administered at T0, T2, and T3. Blood analysis and cardiovascular profile evaluation will be conducted at both T0 and T3.
Feasibility Questionnaire: Both participants and medical professionals will complete a questionnaire on the acceptability and feasibility of the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:
Exclusion Criteria:
Participants will receive traditional lifestyle advices in order to reduce the risk.
Arm Description: Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.
Behavioral: Polygenic Risk Score
Arm Description: Participants will receive an app and a wearable device for the evaluation of various parameters.
Behavioral: Digital app and wearable device
Arm Description: Participants will receive both app and wearable device and PRS information
Behavioral: Polygenic Risk Score · Behavioral: Digital app and wearable device
genetic test for the evaluation of cardiovascular risk
a wearable device connected with its app
Feasibility for the patients
Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).
Time frame: 1 year
Feasibility for the General Practitioners
Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).
Time frame: 1 year
Change in the Lifestyle Category
The lifestyle category will be measured using the Life's Essential 8 tool. A change will be considered achieved if there is a shift towards a more favorable lifestyle category.
Time frame: 12 months
Modification of the Lipid Profile
We will evaluate whether there is a change in the lipid profile compared to the baseline value. The modification of the lipid profile can also be considered as an indicator of the modification of the cardiovascular risk profile measured with the SCORE 2 charts.
Time frame: 12 months
Started Feb 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Catholic University of the Sacred Heart →